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Background: Polycystic ovary syndrome (PCO) is recognized as the most common endocrinopathy in female.
Chemerin is a novel adipocytokine that is expressed in ovary and upregulated in adipose tissue of obese, PCO
patients. To date there is no report about the regulation of ovarian chemerin gene expression after PCO induction
and treatment by insulin sensitizing drugs including pioglitazone and metformin.
Thirty female rats were divided into six experimental groups with five rats in each group including control group,
PCO group (i.m injection of 4 mg estradiol benzoate for 40 days), metformin treated (200 mg/kg/day for 21 days),
pioglitazone treated (20 mg/kg/day, for 21 days), PCO +metformin and PCO + pioglitazone. PCO was detected by
microscopic observation of vaginal smear and treatment by metformin and pioglitazone was initiated one week
after that. Ovarian chemerin expression was analyzed by real time PCR and western blotting.
Results: Our results demonstrated that PCO induction resulted in elevation of chemerin mRNA and protein levels in
ovary in concomitant with incidence of insulin resistance and increasing androgen and progesterone production.
We observed that metformin and pioglitazone attenuated ovarian chemerin expression and improved insulin
resistance and abnormal steroid production in PCO rats.
Conclusion: Based on data presented here we concluded that alteration of ovarian chemerin expression may has
important role in PCO development and manipulation of chemerin expression or signaling by pioglitazone or
metformin can be a novel therapeutic mechanism in the treatment of PCO patients by these drugs.
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Polycystic ovary syndrome (PCO) is recognized as the
most common endocrinopathy in female during the re-
productive age. PCO is characterized by reproductive
dysfunction symptoms such as hyperandrogenic chronic
anovulation due to excess androgen production, men-
strual disturbances, infertility or subfertility and the
presence of enlarged, sclerocystic ovaries. Obesity, insu-
lin resistance, pancreatic-cell dysfunction and impaired
glucose tolerance occur at least in 50% of women with
PCO [1,2]. Previous reports have shown that hyperinsu-
linemia in these patients dysregulates LH secretion and* Correspondence: m.tabandeh@scu.ac.ir
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unless otherwise stated.promotes ovarian androgen secretion resulting in ele-
vation of free androgen level [3].
Over the past decade it has been shown that adi-
pocytes are secretory cells that produce a variety of
proteins with hormonal actions, which collectively have
been called adipocytokines. These cytokines have im-
portant roles in male and female reproductive physiology
by regulation of carbohydrate and lipid metabolism in
adipose or reproductive tissues such as hypothalamus-
pituitary axis, ovary, uterus and embryo [4,5]. Among them,
adiponectin, leptin, resistin and visfatin are the major adi-
pocytokines which their changes in serum or adipose tissue
have been identified in patients with obesity, insulin resist-
ance and PCO [6,7]. Various secretion or gene expression
patterns of adipocytokines or their receptors have been de-
tected in adipose tissue or ovary of PCO patients [8,9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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antly expressed by adipocytes and its gene expression ele-
vates in the adipose tissue of obese animals and human [7].
High correlations have been found between plasma che-
merin level and different features of metabolic syndrome
including body mass index, plasma triglycerides and blood
pressure in human [10]. Chemerin knockdown animals
demonstrate impaired adipocyte gene expression and
unregulated glucose and carbohydrate metabolism [11].
Recent data demonstrate that recombinant chemerin pro-
motes angiogenesis; a mechanism which is essential for
adipose tissue expansion in obese patients [11,12]. Recently,
inhibitory action of chemerin on FSH or IGF-1 induced ste-
roidogenesis have been reported in granulosa cells [13-15].
Serum chemerin increases in women with PCO [16].
Insulin-sensitizing drugs (ISDs) such as metformin or
thiazolidinediones (TZDs) ameliorate reproductive ab-
normalities, restore ovulation and regular estrous cycle,
increase pregnancy rates and reduce androgenic symp-
toms in women with PCO [17,18]. The positive actions
of these insulin-sensitizing agents on adipocytokine se-
cretion or expression in adipose tissue or ovaries of
PCO patients have been described. However the full
mechanism of action of these two drugs in ovaries of
PCO patient is still unraveled and further investigations
remain to elucidate the precise mechanism of actions of
these drugs at molecular levels.
To our knowledge, no study is available that identify
the changes of chemerin gene expression in ovaries of
animals or human with PCO and that compare the ef-
fects of pioglitazone and metformin on its gene expres-
sion in experimental model of PCO. Here for the first
time we showed that ovarian chemerin gene expression




Thirty Female Sprague-Dawley rats (3 month of age)
weighing 150-180 g were housed in a temperature-
controlled room (23 ± 1°C) with a 12 h light/dark cycle
and were provided rat chow (Pars, Tehran, Iran) and
water at libitum.
All animals used were cared for according to the
Guide for the Care and Use of Laboratory Animals by
the National Academy of Sciences (National Institutes
of Health publication No. 86-23). The rats were
allowed to acclimatize for 10 days before the beginning
of the experiment. The estrous cyclicity was monitored
by vaginal smears obtained between 08:00 and 12:00
hours and the rats with abnormal cyclicity were dis-
missed from the experiment.
The rats were divided into six experimental groups
with five rats in each group: 1) healthy control (vehiclecontrol), 2) PCO, 3) metformin treated 4) pioglitazone
treated, 5) PCO and metformin treated and 6) PCO and
pioglitazone treated. PCO was induced by a single i.m
injection of 4 mg estradiol valerate (Loghman Pharma-
ceutical & Hygienic Co, Karaj, Iran) in 0.2 ml sesame oil
(Barij Essense, Kashan, Iran) for 40 days [19] and de-
tected by microscopic observation of vaginal smear. The
presence of prolonged cornified cells for at least two
consecutive estrous cycles was used as successful PCO
induction. Treatment with metformin and pioglitazone
was initiated one week after PCO induction.
Animals in metformin treated groups (groups 3 and 5)
were received 200 mg/kg/day metformin (Loghman
Pharmaceutical & Hygienic Co, Karaj, Iran) by gavage
method for 21 days. Pioglitazone (Dorsa Pharmaceutical
Co. Tehran, Iran) was daily used for the 21 days duration
as the same method as metformin groups with dose of
20 mg/kg/day. Dosages of pioglitazone and metformin
were chosen based on dosages that were clinically used in
human patients (25-30 mg/kg/day for pioglitazone and
200-300 mg/kg/day for metformin).
Tissue and serum sampling
Animals were anesthetized by chloroform and serum sam-
ples were obtained by cardiac puncture, separated by cen-
trifuging at 5,000 rpm for 5 minutes and stored at -20°C
for the subsequent assays. Both ovaries were carefully
trimmed of adhering fat and connective tissue, pooled and
immediately frozen in liquid nitrogen at -80°C. The body
weight and length (nose to anus lenght) of all rats were
determined at the end of study and body mass index
(BMI) was calculated by using following formula as de-
scribed previously; body weight (g)/Length2 (cm2) [20].
Control ovaries were collected from rats at estrous or
proestrous stages of cycle.
Ovarian morphology
Some ovary was removed, cleaned of adherent connective
fat tissue, and fixed in 4% formaldehyde buffer for at least
24 hours. Thereafter the samples were dehydrated and im-
bedded in paraffin. The ovaries were partially longitudin-
ally sectioned (4 μm, every tenth section mounted on the
glass slide), stained with hematoxylin and eosin and the
presence of healthy and atretic follicles, follicular cysts
and corpora lutea was assayed. Antral follicles with pyk-
notic granulosa and theca layers, unhealthy, degenerative
oocyte and filled in antral cavity with numerous apoptotic
derbies were characterized as atretic follicles. Preantral
follicles with degenerative oocyte and pyknotic granulosa
layer were assigned as atretic follicles.
Hormone and glucose assays
Serum insulin levels were measured by using the Rat ELISA
kits (Mercodia, Sweden) according to the manufacturer’s
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μg/L. The limit of detection of insulin was 0.01 μg/L and
the intra-assay and interassay coefficients of variation were
less than 4% and 8.13%, respectively. The calibrator ranges
were between 0-10 μg/L (first calibrator at 0.01 μg/L).
The progesterone (P4) and testosterone (T) concentra-
tions were determined by using a commercial radio-
immunoassay kit (Immunotech, Radiová, Czech Republic).
The limit of detection of P4 was 0.1 ng/ml, and the intra-
assay and interassay coefficients of variation were less than
10% and 11%, respectively. The calibrator ranges were be-
tween 0 - 100 ng/mL (first calibrator at 0.1 ng/mL). The
limit of detection of T was 0.1 ng/ml, and the intra-assay
and interassay coefficients of variation were less than
12.1% and 11.2%, respectively. The calibrator ranges were
between 0 – 25 ng/mL (first calibrator at 0.1 ng/mL).
Blood glucose was determined by glucose oxidase
method (Pars Azmoon, Tehran, Iran) as described by
manufacturer.
HOMA-IR estimation
HOMA-IR was estimated through previously described
formula (fasting glucose × fasting insulin/22.5) and rep-
resented by unit of mmol/L × μU/ml [21].
RNA preparation
Total RNA was extracted from ovaries using TriPure
total RNA isolation kit according to the manufacturer’s
procedure (Roche Molecular System, USA), dissolved in
dimethyl pyrocarbonate treated water and quantified at
a wavelength of 260 nm by nanodrop spectrophotometry
(Eppendorf, Hamburg, Germany). The RNA with optical
density absorption ratio OD260 nm/OD280 nm between
1.8 and 2.0 was used for reverse transcription (RT) reac-
tion. Genomic DNA was removed by treating 1 μg of
isolated RNA with 2 units of DNase I (Fermentas Inc,
Vilnius, Lithuania).
Reverse transcription − polymerase chain reaction
Reverse transcription was done in a total volume of 20-
μl by using an AmpliSence cDNA synthesis kit (Ampli-
Sens Enterovirus-Eph, Russia) as recommended by the
manufacturer. The PCR reactions was performed in a
25-μl reaction using Taq DNA polymerase (Cinagen Co,
Iran) and a thermal cycler (Eppendorf Mastercycler,
Hamburg, Germany). Specific sets of primers (BIO-
NEER, Seoul, South Korea) that used for amplification
of rat chemerin were as follows; forward: 5′-ATG
GCGGGCAACGGCGCCAT-3′ and reverse: 5′-CCAT
CAACGTCGTCAACTAA-3′. Thermal conditions for
amplification of chemerin were 35 cycles consisting of
denaturing at 94°C for 1 min, annealing at 58°C for
1 min, extension at 72°C for 1 min, with an initial de-
naturing step at 95°C for 10 min and a final extensionstep at 72°C for 10 min. cDNA from adipose tissue was
used as positive control. Expression of chemerin in rat
ovaries was confirmed by visualization of PCR product
on agarose gel electrophoresis (1%).
Real time PCR
To evaluate the levels of chemerin gene expression in
ovaries of different animals quantitative real-time PCR
(qRT-PCR) was performed using the ABI Step One plus
real-time PCR detection system (ABI plus; Applied Bio-
systems, USA), and qPCR™ Green master kit for SYBR
Green I® (Applied Biosystems, USA). Relative expression
level of chemerin transcript was compared to GAPDH
as housekeeping gene. Specific sets of primers (Macro-
gen, Seoul, South Korea) that were used for amplifi-
cation of rat GAPDH [GenBank: NM_017008.4] and
chemerin [GenBank: NM_001013427] genes were de-
signed using Beacon Designer 7.1. Sequences of primers
for amplification of rat GAPDH and chemerin (BIONEER,
Seoul, South Korea) were as follows; rat chemerin: 5′-
TGTGGACAGTGCTGATGACCTGTT-3′ and 5′-CAGT
TTGATGCAGGCCAGGCATTT-3′ and rat GAPDH: 5′-
CTCATCTACCTCTCCATCGTCTG-3′ and 5′-CCTGC
TCTTGTCTGCCGGTGCTTG-3′ Real time PCR reac-
tions were performed with the following settings: 5 mi-
nutes of pre-incubation at 95°C followed by 40 cycles for
15 seconds at 95°C and 45 second at 60°C. Reactions were
performed in triplicate. A reaction without cDNA was
performed in parallel as negative control.
Relative quantification was performed according to the
comparative 2-ΔΔCt. For analysis of qRT-PCR results
based on ΔΔCt method StepOne™ software was used.
The result for the gene expression was given by a unit-
less value through the formula 2-ΔΔCt. Validation of assay
to check that the primer for the GAPDH and chemerin
had similar amplification efficiencies was performed as
described previously [22].
Western blotting
Total protein from isolated ovaries was precipitated after
RNA and DNA isolation using TriPure total RNA isola-
tion kit according to the manufacturer’s procedure (Roche
Molecular System, USA) and its concentration was mea-
sured using Bradford method as described previously [23].
Twenty five μl of each protein sample (1 μg/μl) were
mixed with 25 μl Laemmli sample buffer supplemented
with 2-mercaptoethanol at a final concentration of 7.5%
(vol/vol). The samples were heated for 15 min at 65°C,
separated by 10% SDS-PAGE and electrophoretically
transferred to a nitrocellulose membrane (Schleicher &
Schuell, Inc., Keene, NH). The filters were blocked by in-
cubation for 1 h in PBS with 5% nonfat milk. Blots were
then washed in PBS-Tween and immunoblotted with
primary antibody against mouse chemerin (Abcam,
Figure 1 Ovarian features in normal rats (A), estradiol induced PCO rats, (B) PCO rats treated with pioglitazone (C) and PCO rats
treated with metformin (D). Normal rats displayed follicles at different stages and the presence of corpora lutea (CL) (A), while estradiol
treatment resulted in formation of higher numbers of atretic and cystic follicles (CF) and the absence of CL (B). Metformin and pioglitazone
treated rats (C and D) exhibited lower numbers of CF, higher numbers of antral follicles and growing young CL. H & E
staining (magnification × 40).
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tion of primary antibody was done using goat anti rabbit
HRP-conjugated antibody (Abcam, Cambridge, UK, Art
No; ab98467) at 1:1000 ratio and DAB reagent (Sigma Al-
drich, Germany). Densitometric quantification of chemerin
proteins in relation to GAPDH as calibrator was performed
using Image J software (National Institutes of Health).
Western blot was done in three independent experiments
for each sample.
Statistical analyses
Data analyses were done using the SPSS 16.0 software
package (SPSS Inc., Chicago, IL, USA). Two-way analysis of
variance (ANOVA) and general linear model was fit to
evaluate the effect of PCO status (PCO vs. control) and
treatments (treatment with metformin or pioglitazon vs.
no treatment) on each variable. The two-way ANOVA
model is given by Yijk = μ + αi + βj + (αβ)ij, where αi and βj
represent the effects of PCO induction and treatment, and
(αβ)ij represents the interaction of two factors. The Spear-
man rank correlation coefficient was used to estimate the
correlation between chemerin gene expression and differ-
ent parameters. All experimental data were presented as
the mean ± SD. The level of significance for all tests was
set at P < 0.05.Result
The ovaries in the control group exhibited a typically
normal appearance with small and medium sized antral
follicles and corpora lutea (Figure 1A). The ovaries in
the PCO group displayed typical PCO-like changes in-
cluding presence of higher numbers of atretic and cystic
follicles compared with the control group (Figure 1B).
Metformin and pioglitazone treated rats exhibited lower
numbers of atretic and cystic follicles, higher numbers of
antral follicles and growing young corpora lutea compared
with PCO group (Figure 1C-D). Restoration of normal fol-
licular appearance was more pronounced in metformin
treated rats compared with pioglitazon treated animals
(Figure 1C-D).
The real time-PCR and western blot results demon-
strated that chemerin mRNA and protein levels were el-
evated in ovaries of PCO rats when compared to that in
healthy animals (P < 0.05) (Figure 2). The chemerin gene
expression levels were decreased in ovaries of PCO rats
in response to treatment with metformin and pioglitazone
compared to untreated PCO rats (p < 0.05) (Figure 2).
Metformin and pioglitazone had no effects on the levels of
chemerin mRNA and protein in healthy treated rats in re-
lation to healthy untreated animals regardless of PCO sta-
tus (Figure 2) (p > 0.05).
Figure 2 Chemerin protein (A) and mRNA levels (B) in rat ovaries after PCO induction and treatment with pioglitazone and metformin
(n = 5 in each group). Chemerin was up-regulated in ovary of PCO rats compared with control animals, whereas its level decreased after treatment
with metformin and pioglitazone. Data were presented as the mean ± SD. Different letters denote differences among groups at P < 0.05.
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lin levels were higher in the PCO induced rats (1.92 ±
0.38 fold) when compared with normal untreated group
(p <0.05) after controlling for the effect of treatment.
Treatment of PCO rats with metformin and pioglitazone
resulted in reduction of glucose (1.36 ± 0.27) and insulin
(1.82 ± 0.36) levels in relation to PCO untreated rats
(p < 0.05) (Figures 3 and 4). In healthy treated groups
plasma insulin and glucose levels had no differences with
healthy untreated animals (Figures 3 and 4), (p > 0.05) after
controlling for PCO status.The HOMA-IR index, which reflects whole body insu-
lin resistance, was increased in PCO animals (3.63 ± 0.41
fold) (p < 0.05) (Figure 5) regardless of treatments. Met-
formin and pioglitazone induced reduction of HOMA-IR
in PCO rats about 2.8 fold compared with untreated PCO
animals (p < 0.05) (Figure 5). Healthy treated rats did not
show clear changes in HOMA-IR level in relation to
healthy untreated rats after controlling PCO status.
The plasma concentrations of T and P4 are shown in
Figures 6 and 7 respectively. We found a 1.8 ± 0.3 fold
increase of plasma T and a 6.9 ± 0.8 fold increase of P4
Figure 3 Serum glucose levels (mg/dl) in normal rats (n = 5), PCO induced rats (n = 5) and treated rats with metformin and
pioglitazone (n = 5). Serum glucose was elevated in PCO rats compared with control animals. Treatment of PCO rats with metformin and
pioglitazone resulted in reduction of glucose level in relation to PCO untreated rats. Data were presented as the mean ± SD. Different letters
denote differences among groups at P < 0.05.
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regardless of treatments. We found that in treated PCO
rats, T concentrations were decreased by 1.2 ± 0.3 fold
and 1.9 ± 0.5 fold after metformin and pioglitazone treat-
ment respectively (p < 0.05) (Figure 6). The reduction of
T level was more pronounced in PCO rats in the pres-
ence of pioglitazone compared with metformin (p < 0.05)
(Figure 6), while metformin was more effective in redu-
cing P4 concentration in this group (p < 0.05) (Figure 7).
Spearman Rank correlation analyses demonstrated that
ovarian chemerin gene expression was positively associated
with P4 (p < 0.01), HOMA-IR, BMI, insulin and glucose
levels (p < 0.05) (Table 1). Δ chemerin gene expression inFigure 4 Serum insulin levels (ug/L) in normal rats (n = 5), PCO induce
(n = 5). Serum insulin level was considerably higher in PCO rats compared
and pioglitazone decreased the over-secretion of insulin in relation to PCO
denote differences among groups at P < 0.05.treated PCO animals had positive correlation with Δ insu-
lin, Δ HOMA-IR and Δ P4 (p < 0.05) (Table 1).
Discussion
PCO is a heterogeneous syndrome characterized by hy-
perandrogenism, insulin resistance and obesity [24]. The
mechanism that is responsible for insulin resistance is un-
clear and several hypotheses have been suggested. Because
obesity is linked to insulin resistance and many women
with PCO are obese, it is possible that, at least in a sub-
group of patients, insulin resistance is worsened by ex-
cessive adipose mass or abnormal secretion or action of
adipocytokines [25]. Chemerin is a newly identifiedd rats (n = 5) and treated rats with metformin and pioglitazone
with that in normal animals. Treatment of PCO rats with metformin
untreated rats. Data were presented as the mean ± SD. Different letters
Figure 5 HOMA-IR index (mmol/L × uU/ml) in normal rats (n = 5), PCO induced rats (n = 5) and treated rats with metformin and
pioglitazone (n = 5). Rats with PCO showed insulin resistance compared with normal rats, while treatment of those with metformin and
pioglitazone attenuate insulin resistance in relation to PCO untreated rats. Data were presented as the mean ± SD. Different letters denote
differences among groups at P < 0.05.
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and positively correlate with markers of the metabolic
syndrome such as body mass index, triglycerides, high-
sensitivity C-reactive protein [15,26]. Recently Tan et al
demonstrated an increase of serum and subcutaneous and
omental adipose tissue chemerin expression in women with
PCO [10]. Chemerin is also expressed in ovary of animal
and human, but few data exists on regulation of chemerin
gene expression in polycystic ovaries [14,27]. Here we
present novel data showing an increase of chemerin gene
expression in rat ovary after induction of PCO. The ani-
mals in PCO group gained more weight, had higher
plasma insulin and glucose levels and showed an elevation
of HOMA-IR; an index of insulin resistance. Our findingsFigure 6 Serum testosterone (T) levels (ug/L) in normal rats (n = 5), PC
pioglitazone (n = 5). Induction of PCO caused an increasing the T level, w
were presented as the mean ± SD. Different letters denote differences amowas in agreement with results of Wang et al which has
shown the higher level of chemein expression in the ovary
of dihydrotestosterone (DHT) induced PCO rats [15]. Sev-
eral experiments have demonstrated that chemerin may
play a role in pathophysiology of PCO in animal or human
by direct action on ovary [10,13,14]. We know that forma-
tion of polycystic ovaries is critically associated with ab-
normal steroidogenesis. It has been found that chemerin
decreases estradiol secretion and suppressed FSH-induced
progesterone and estradiol secretion in preantral fol-
licles and granulosa cells by inhibition of aromatase and
p450scc expression [13].
It is also well recognized that development of polycys-
tic ovaries is associated with new blood vessel formationO induced rats (n = 5) and treated rats with metformin and
hile metformin and pioglitazone attenuated over secretion of T. Data
ng groups at P < 0.05.
Figure 7 Serum progesterone (P) levels (ug/L) in normal rats (n = 5), PCO induced rats (n = 5) and treated rats with metformin and
pioglitazone (n = 5). Induction of PCO caused an increasing the P level, while metformin and pioglitazone attenuated over secretion of T. Data were
presented as the mean ± SD. Different letters denote differences among groups at P < 0.05.
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merin on ovarian angiogenesis, however it is plausible
that chemerin may act as angiogenic factor. Recently
Bozauglo et al using an in vitro angiogenesis assay has
shown that chemerin induced the formation of capillary-
like structures, a process which occur in obese patient and
result in adipose tissue expansion [12]. These observations
lead to the hypothesis that increasing the chemerin gene
expression in ovary of PCO rats may alter ovarian steroido-
genesis or angiogenesis and may play a role in the develop-
ment and progression of this reproductive disorder.
It has been demonstrated that alteration of metabolic
and endocrine function of adipocytes result in a higher se-
cretion of proinflammatory substances including tumor
necrosis factor alpha (TNF-α) and interleukin-6 (IL-6)Table 1 Correlation between chemerin gene expression in
ovaries of PCO rats with insulin, glucose, HOMA-IR index,
testosterone, progesterone and body mass index (BMI)







p r p r
0.0847 0.361 0.0327 0.661* Glucose (mg/dl)
0.0432 0.578* 0.0087 0.754** Insulin (μg/l)
0.0916 0.291 0.0414 0.523* Testosterone (ng/ml)
0.0382 0.619* 0.0091 0.827** Progesterone (ng/ml)
0.0478 0.564* 0.0276 0.678* HOMA-IR
0.0739 0.378 0.0312 0.654* BMI
*Correlation is significant at the 0.05 level.
**Correlation is significant at the 0.01 level.
Correlation coefficient (r) and statistical significance (P) are indicated.
(Δ) change in chemerin gene expression level after treatment.[29]. Many reports have demonstrated that these potent in-
flammatory compounds alter normal physiology of ovary
such as steroidogenesis and enhance the risk of PCO devel-
opment [17,30]. Presence a positive association between in-
creasing body weight and ovarian chemerin gene expression
in this study raises the possibility that alteration of chemerin
gene expression in ovary of PCO animals may be, in some
part, due to increasing fat mass and releasing higher in-
flammatory mediators such as IL-6 and TNF-α. This hy-
pothesis is supported by the fact that TNF-α increases
adipocyte chemerin and elevation of serum TNF-α leads
to higher systemic chemerin in mice [31].
We also found the higher plasma insulin level in animals
with PCO compared with healthy rats and its positive as-
sociation with ovarian chemerin gene expression. Interes-
tingly, insulin elevates chemerin in human adipose tissue
explants in vitro, and systemic chemerin increases after
prolonged hyperinsulinemia in healthy individuals. This
finding suggests that hyperinsulinemia which occur in our
experiment may enhance the chemerin gene expression in
polycystic ovaries and it may have role in progression of
impaired steroid production [32].
Consistent with previous results, our study showed that
chemerin has role in PCO development and manipulation
of chemerin gene expression or its signaling may be a novel
therapeutic approaches in the treatment of PCO patients.
To clarify this hypothesis we test the effect of pioglitazone
and metformin on the ovarian chemerin gene expression in
normal and PCO animals. To our knowledge, this is the
first report demonstrating that treatment of PCO rat with
pioglitazone and metformin alter chemerin gene expression
in the ovary. Here we reported for the first time that 21 days
treatment of PCO rats with metformin and pioglitazone re-
duced ovarian chemerin mRNA and protein abundance with
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mals. Reduction of chemerin gene expression was more pro-
nounced in PCO rats in the presence of pioglitazone
compared with metformin, while these drugs had no effects
on the basal levels of ovarian chemerin mRNA and protein
in healthy animals. We also found improvement of insulin
resistance in animals treated with pioglitazone or metformin.
Animals in these groups showed lower plasma insulin and
glucose level and HOMA-IR compared with PCO animals.
Pioglitazone and metformin are the most important
insulin-sensitizing agents currently used most often in clin-
ical practice to improve insulin resistance of PCO patients
via different mechanisms which are not thoroughly under-
stood [33,34]. A diverse beneficial effect of pioglitazone
and metformin on the treatment of PCO has been de-
scribed in recent years [35]. Alteration of numerous genes
involved in different ovarian functions such as cell prolif-
eration, steroid production and new blood formation by
these drugs have been detected and it demonstrate that
their positive effects on ovarian function in PCO patients
may be multifactorial [35,36]. Recently it has been found
that troglitazone or metformin reduce the secretion of
chemerin from adipoe tissue and metformin can also re-
duces chemerin blood levels in concomitant with improv-
ing insulin sensivity and decreasing BMI in women with
PCO [10]. It has also been demonstrated that both drugs
have anti-angiogenic actions, suppresses ovarian androgen
production and reduce the secretion of proinflammatory
factors including IL-6 and TNF-α [37-39]. Given our find-
ings and those from other groups we hypothesized that
these drugs may improve functional and endocrine distur-
bances of polycystic ovaries, in some part, by suppression
of ovarian chemerin gene expression and attenuation of its
adverse effect on normal functions of polycystic ovaries.
Conclusion
In conclusion, using a murine model of PCO, we provided
novel evidence that chemerin is an important adipocyto-
kine which may contribute to the dysregulation of ovarian
function in PCO. Our study indicated that ovarian che-
merin gene expression is associated with several key pa-
rameters of the metabolic syndrome in PCO status. Oral
administration of pioglitazone and metformin to PCO rats
altered the ovarian expression of chemerin genes. These re-
sults suggest that some therapeutic effects of metformin
and pioglitazone in PCO may be due to their direct actions
on ovarian chemerin gene expression.
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